Based on the recent earnings call from Eli Lilly & Company, it is recommended to take an 'underweight' investment stance on the company. The company's revenue growth of 7% was driven by volume growth in their pharmaceutical business, but there are concerns about the FDA's complete response letter for baricitinib in rheumatoid arthritis. Additionally, the company's focus on innovation and investment in new products may not yield significant margin gains in the near future. There is also caution around potential large cost restructuring programs that could disrupt the company's financial performance. Furthermore, the pursuit of M&A opportunities may face constraints related to pricing and strategic fit. Overall, the company's growth prospects may be overshadowed by regulatory challenges and potential capital constraints. It is important to stay cautious with regards to investing in Eli Lilly & Company based on these recent developments.